Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies
| Autor: | Giuseppe Biondi-Zoccai, Elena Bignami, Luigi Tritapepe, Anna Mizzi, Giovanni Landoni, Vincenzo De Santis, Giovanna Bruno, Chiara Gerli, Alberto Zangrillo |
|---|---|
| Přispěvatelé: | Zangrillo, Alberto, Biondi Zoccai, G, Mizzi, A, Bruno, G, Bignami, E, Gerli, C, De Santis, V, Tritapepe, L, Landoni, Giovanni |
| Rok vydání: | 2009 |
| Předmět: |
Inotrope
medicine.medical_specialty Cardiotonic Agents Endpoint Determination medicine.medical_treatment Risk Assessment law.invention law Internal medicine Humans Medicine Postoperative Period Myocardial infarction Cardiac Surgical Procedures Simendan Randomized Controlled Trials as Topic Mechanical ventilation biology business.industry Myocardium Hydrazones Reproducibility of Results Heart Atrial fibrillation Levosimendan medicine.disease Troponin Intensive care unit Cardiac surgery Pyridazines Treatment Outcome Anesthesiology and Pain Medicine Anesthesia biology.protein Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Cardiothoracic and Vascular Anesthesia. 23:474-478 |
| ISSN: | 1053-0770 |
| Popis: | Objectives: The authors performed a meta-analysis to investigate the effects of levosimendan in cardiac surgery. Inotropic drugs have never shown beneficial effects on outcome in randomized controlled studies, with the possible exception of levosimendan. Design: A meta-analysis. Setting: Hospitals. Participants: A total of 139 patients from 5 randomized controlled studies were included in the analysis. Interventions: None. Measurments and Main Results: Four investigators independently searched BioMedCentral and PubMed. Inclusion criteria were random allocation to treatment, and comparison of levosimendan versus control performed on cardiac surgery patients. Exclusion criteria were duplicate publications, nonhuman experimental studies, and no outcome data. The endpoint was postoperative cardiac troponin release. Levosimendan was associated with a significant reduction in cardiac troponin peak release (weighted mean difference = 2.5 ng/dL [-3.86, -1.14], p = 0.0003) and in time to hospital discharge (weighted mean difference = -1.38 days [-2.78, 0.03], p = 0.05). No other relevant outcome (mortality, myocardial infarction, atrial fibrillation, time on mechanical ventilation, and intensive care unit stay) was improved in those patients receiving levosimendan. Conclusions: Levosimendan has cardioprotective effects, resulting in reduced postoperative cardiac troponin release. (C) 2009 Elsevier Inc. All rights reserved |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect